Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Toronto
$27,000.00
Orthologous Intracellular Receptor Pathways for Modulation of T-Cell Gene Expression
EF 2025-26
Résumé
As new breakthroughs for cancer treatment and therapy are made, it is clear that a better understanding of JAK/STAT signalling is necessary as it relates to regulation of key intracellular processes including embryonic development, cell proliferation, and immune system function and development. This signalling process involves extracellular cytokines binding to their associated membrane receptors, which in turn activate Janus Kinases (JAKs) and Signal Transducers and Activators of Transcription (STATs) for downstream signalling. Dysregulation is possible and can occur from mutations at any stage of the pathway, which can lead to the onset of autoimmune diseases, cancer, and immunodeficiency due to excess or insufficient JAK/STAT signalling.
Many studies describe the need for strict regulation of JAK/STAT signalling as a therapeutic approach to treat these diseases. Clinical studies aiming to downregulate JAK/STAT signalling have developed JAK inhibitors and have shown preliminary success. Other studies aiming to upregulate signalling have developed orthologous signalling pathways similar to endogenous JAK/STAT signalling to activate a specific STAT protein. This project will create a modular system, expanding on previous orthologous signalling research, in order to simultaneously activate any and all human STAT proteins. To achieve this, first the modular system will be designed and validated in a HEK cell transfection assay to activate a specific STAT. Next, the modular system will be expanded to simultaneously activate each STAT protein using similar assays in HEK cells and phospho-flow methodologies. Lastly, the modular system will be packaged using lipid nanoparticles (LNPs) for effective transfection in HEK and CAR-T cells.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
572598
Name
Law Cobb Justin C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Orthologous Intracellular Receptor Pathways for Modulation of T-Cell Gene Expression
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Jak/Stat Signalling; Modular System; Receptor Engineering
Abstract
As new breakthroughs for cancer treatment and therapy are made, it is clear that a better understanding of JAK/STAT signalling is necessary as it relates to regulation of key intracellular processes including embryonic development, cell proliferation, and immune system function and development. This signalling process involves extracellular cytokines binding to their associated membrane receptors, which in turn activate Janus Kinases (JAKs) and Signal Transducers and Activators of Transcription (STATs) for downstream signalling. Dysregulation is possible and can occur from mutations at any stage of the pathway, which can lead to the onset of autoimmune diseases, cancer, and immunodeficiency due to excess or insufficient JAK/STAT signalling.
Many studies describe the need for strict regulation of JAK/STAT signalling as a therapeutic approach to treat these diseases. Clinical studies aiming to downregulate JAK/STAT signalling have developed JAK inhibitors and have shown preliminary success. Other studies aiming to upregulate signalling have developed orthologous signalling pathways similar to endogenous JAK/STAT signalling to activate a specific STAT protein. This project will create a modular system, expanding on previous orthologous signalling research, in order to simultaneously activate any and all human STAT proteins. To achieve this, first the modular system will be designed and validated in a HEK cell transfection assay to activate a specific STAT. Next, the modular system will be expanded to simultaneously activate each STAT protein using similar assays in HEK cells and phospho-flow methodologies. Lastly, the modular system will be packaged using lipid nanoparticles (LNPs) for effective transfection in HEK and CAR-T cells.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Law Cobb, Justin C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~